Followers | 275 |
Posts | 70785 |
Boards Moderated | 6 |
Alias Born | 11/21/2011 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 06, 2011 5:42:46 PM
~~~~~~~~~~~~~~~~~~~~~~~~~~
MARINA DEL REY, Calif., Dec 6, 2011 (GlobeNewswire via COMTEX) -- Atlas Therapeutics Corporation ATTH -2.00% , dba The Muscle Company, is proud to announce that its innovative product, MYO-T12(R) is now available on Bodybuilding.com, the world's number one online bodybuilding website and supplement store. As the most visited bodybuilding and fitness site on the web, Bodybuilding.com sells directly from manufacture to consumer, cutting out the middleman and only sells the highest quality of products.
MYO-T12(R) is the world's first clinically validated, myostatin-inhibiting dietary supplement. It breaks down the barriers that until now have prevented people from reaching their fitness goals. MYO-T12(R) works by modulating the body's level of myostatin, a genetic protein that restricts muscle growth no matter how hard a person trains and lifts weights. It has been clinically validated to reduce the average serum myostatin levels in the body by up to 46 percent within 12 to 18 hours after one serving.
"We are very proud to have the product for sale on Bodybuilding.com. This marks a big milestone for MYO-T12 as Bodybuilding.com is the industry gold standard for supplement sales," said JB Bernstein, CEO of Atlas Therapeutics.
About Atlas Therapeutics Corporation
Atlas Therapeutics Corporation owns the rights to MYO-T12(R), the world's only clinically validated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12(R) is manufactured to optimize biological activity and has the potential to redefine existing standards of physical enhancement. Atlas is focused on preserving and growing the existing brand identity of MYO-T12(R) by refining its technical profile, and designing and implementing a marketing and sales strategy to increase penetration of the product into the existing health and fitness community.
For more information on Atlas Therapeutics Corporation, visit www.AtlasTherapeutics.com .
For more information of MYO-T12(R), visit www.MYOT12.com
http://www.globenewswire.com/newsroom/prs/?pkgid=10042
Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Atlas Therapeutics Corporation
CONTACT: ATLAS/MYO-T12(R) MEDIA CONTACT:
Lisa LaFon - (602) 954-4678
llafon@atlastherapeutics.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM